Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.
Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.
Evgin L, et al.
Mol Ther Oncolytics. 2016 Nov 16;3:16027. doi: 10.1038/mto.2016.27. eCollection 2016.
Mol Ther Oncolytics. 2016.
PMID: 27909702
Free PMC article.